- This event has passed.
Precision Medicine/ELSI Seminar – David L. Veenstra, PharmD
April 8, 4:00 pm - 5:00 pm
Advances in Precision Medicine Seminar/Seminar on Ethical, Legal and Social Implications of Genetics
“Should we be conducting genomic screening in US adults to assess risk of future disease?”
David L. Veenstra, PharmD, PhD (University of Washington)
Professor, Associate Director, Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, Department of Pharmacy
Dr. Veenstra’s primary research interests are the clinical, economic, and policy implications of using genomic information in healthcare. His major research projects include evaluation of the cost effectiveness of population-level genomic screening, pharmacogenomics in diverse populations, and evidence thresholds, research prioritization, and preferences for precision medicine. His research has been funded through grants from the National Human Genome Research Institute, Centers for Disease Control, and the National Cancer Institute.
Rapidly decreasing genetic testing costs have brought population-wide genomic screening within the realm of possibilities. But high-risk monogenic conditions are rare and prevention strategies will lead to additional healthcare costs. Dr. Veenstra will present the results of decision-analytic simulation models assessing the cost effectiveness of genomic screening for risk of breast and ovarian cancer, colorectal cancer, and cardiovascular disease.
Monthly seminar series hosted by the Center for Research on Ethical, Legal & Social Implications of Psychiatric, Neurologic & Behavioral Genetics and the Precision Medicine Resource of the Irving Institute for Clinical and Translational Research and featuring leaders in the Precision Medicine field from across the nation.